Their research found that psoriasis patients and IMQ-treated mice both had elevated PCSK9, and that inhibiting PCSK9 could lessen the inflammatory response in psoriasis by inhibiting KCs proliferation and the NF-κB pathway (148). Here, NFKB1 is linked to psoriasis.